Generative AI for Retail Innovation
Book Announcement
Updates every hour. Last Updated: 29-Oct-2026 09:17 ET (29-Oct-2026 13:17 GMT/UTC)
Bentham Books announces the release of Generative AI for Retail Innovation, a timely reference exploring how emerging AI technologies are reshaping retail through smarter decision-making, personalized customer experiences and sustainable business growth.
A research team from the Vision and Action Laboratory, Visual Perception and Cognition Laboratory, and Cognitive Neurotechnology Unit in the Department of Computer Science and Engineering at Toyohashi University of Technology, led by Associate Professor Hideki Tamura, has shown that the temporal patterns of pupillary responses differ depending on whether observers evaluate the same object images in terms of glossiness or attractiveness. The research team used images of 60 everyday objects as visual stimuli and measured pupil diameter while participants separately evaluated their perceived glossiness and attractiveness. Exactly the same set of images was used in both tasks. The results showed that higher glossiness ratings were associated with greater pupil constriction during a relatively early time window centered at approximately 1 second after stimulus onset. In contrast, higher attractiveness ratings tended to be associated with greater pupil dilation at later time points. These findings suggest that even when viewing the same objects, the temporal characteristics of pupillary responses may differ depending on what observers are evaluating.
The study was published in Journal of Vision on September 1, 2026.
https://doi.org/10.1167/jov.26.9.1Researchers have developed a laser-assisted method that rapidly detects tiny amounts of CEACAM-5, a colorectal cancer biomarker, in blood. The technique enhances antibody–antigen interactions and achieves detection even at low concentrations within minutes. The researchers also identified nanoscale CEACAM-5 aggregates that may enhance the method’s sensitivity.
Researchers at The University of Texas at Austin have teamed up with pharmaceutical leader Eli Lilly and Company to uncover new information about mRNA lipid nanoparticles (LNPs), the technology behind COVID-19 vaccines and other important treatments, and how to make it more effective.